Abstract
The present study addressed the question as to whether prostate-specific antigen reverse transcriptase-polymerase chain reaction (PSA RT-PCR) could be used to identify prospectively men who have prostate cancer and to help determine which patients with an initially negative biopsy would benefit from rebiopsy. PSA RT-PCR was performed prospectively on 90 patients who were to have a prostate biopsy because of an elevated PSA level, an abnormal digital rectal examination, or both. PSA RT-PCR was performed, and the sensitivity of the test was enhanced by hybridization of the PCR with a32p-labeled PSA cl)NA probe (exons 3–5). Of the 90 men, 36 (40%) had prostate cancer on biopsy. Of these 36 men, 5 (13.9%) had a positive PSA RT-PCR finding, whereas 31 (84.1%) tested negative. Of 54 men with negative biopsies, 8 (14.8%) had a positive PSA RT-PCR result. The sensitivity of PSA RT-PCR for the detection of biopsy-proven prostate cancer was 13.9% and the specificity was 85.2%. Only 3 of 12 (25%) patients with advanced disease had a positive test result. The sensitivity of PSA RT-PCR for the detection of biopsy-proven prostate adenocarcinoma in men suspected of having prostate cancer is poor. Indeed, men without biopsy-proven prostate cancer are just as likely to have a positive result in the PSA RT-PCR as are men with cancer. Whether these men with negative prostate biopsies and positive PSA RT-PCR findings may eventually develop prostate cancer remains to be determined. At this time, PSA RT-PCR for the prospective detection of prostate cancer should be considered investigational.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Catalona WJ, Smith DS, Ratliff TL, Dodd KM, Coplen DE, Yuan JJJ, Petros JA, Andriole GL (1991) Measurement of prostatic-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156–1161
Diamandis EP (1995) Prostate cancer, prostate-specific antigen, and the polymerase chain reaction (editorial). Clin Chem 41: 177–179
Epstein JI, Pizov G, Walsh PC (1993) Correlation of pathologic findings with progression after radical prostatectomy. Cancer 71: 3582–3593
Erlich HA (ed) (1992) PCR technology: principles and applications for DNA amplification. W.H. Freeman, New York, pp 10–15
Feinberg AP, Vogelstein B (1983) A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132: 6–13
Gussow D, Rein R, Ginjaar I, Hochstenbach F, Seemann G, Kottman A, et al (1987) The human β-2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol 139: 3132–3138
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809–1878
Humphrey PA, Keetch DW, Catalona WJ (1995) Morphometric analysis of prostate cancers detected at initial versus serial prostatic biopsies (abstract 276). J Urol 153: 297A
Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, De Blasio A, Edwards ET, Wise GJ, Heston WDW (1994) Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate specific antigen-based assays. Cancer Res 54: 6306–6310
Israeli RS, Miller WH, Su SL, Samadi DS, Powell T, Heston WDW, et al (1995) Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 153: 573–577
Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, et al (1994) Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43: 765–775
Keetch DW, Catalona WJ, Smith DS (1994) Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151: 1571–1574
Klobeck HG, Combriato G, Schultz P, Arbusow V, Fittler F (1989) Genomic sequences of human prostate specific antigen (PSA). Nucleic Acids Res 17: 3981
Lippman HR, Ghiatas AA, Sarosdy MF (1992) Systematic transrectal ultrasound guided prostate biopsy after negative digitally directed prostate biopsy. J Urol 147: 827–829
Lundwall A, Lilja H (1987) Molecular cloning of a human prostate specific antigen cDNA. FEBS Lett 214: 317–322
Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer statistics. Cancer 46: 5–27
Smith MR, Biggar S, Hussain M (1995) Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 55: 2640–2644
Sokoloff MH, Tso CL, Kaboo R, Nelson S, Ko J, Dorey F, Figlin RA, Pang S, DeKernion J, Belldegrun A (1996) Quantitative polymerase chain reaction does not improve prostate cancer staging: a clinic pathological molecular analysis of 121 patients. J Urol 156: 1560–1566
Van Every MJ, Rooney B (1993) Comparison of ultrasound guided and digitally directed transrectal biopsy of palpable prostate lesion. Urology 42: 677–679
Yu H, Diamandis EP, Levesque M, Asa SL, Monne M, Croce Cm (1995) Expression of the prostate specific antigen gene by a primary ovarian carcinoma. Cancer Res 55: 1603–1606
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goldman, H.B., Israeli, R.S., Lu, Y. et al. Can prostate-specific antigen reverse transcriptase-polymerase chain reaction be used as a prospective test to diagnose prostate cancer?. World J Urol 15, 257–261 (1997). https://doi.org/10.1007/BF01367664
Issue Date:
DOI: https://doi.org/10.1007/BF01367664